Paper2902689
In vivo administration of anti-CD3 prevents malignant progressor tumor growth.
Ellenhorn JD and 3 others. Science, 1988. Cited by 113 papers, by iCite.
Cite this record
ConductScience Library. In vivo administration of anti-CD3 prevents malignant progressor tumor growth. Papers, record 2902689. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/2902689
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Publication types
- Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.
- PubMed
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antigens, Differentiation, T-Lymphocyte | Major topic |
| Lymphocyte Activation | Major topic |
| Neoplasms, Experimental | Major topic |
| Receptors, Antigen, T-Cell | Major topic |
| T-Lymphocytes | Major topic |
| Animals | |
| Antigens, Surface | |
| CD3 Complex | |
| Dose-Response Relationship, Immunologic | |
| Immunosuppression Therapy | |
| Immunotherapy | |
| Lymph Nodes | |
| Mice | |
| Neoplasm Transplantation | |
| Receptors, Interleukin-2 | |
| Thy-1 Antigens |
Source PubMed
Cited by20
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 113 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 39345919 | Drug overdose deaths during prison riots and mental states of prisoners: a case study. | Front Psychiatry | 2024 | https://conductscience.org/library/papers/39345919 | PubMed |
| 37724258 | Therapeutic antibodies for precise cancer immunotherapy: current and future perspectives. | Med Rev (2021) | 2022 | https://conductscience.org/library/papers/37724258 | PubMed |
| 36831533 | Modulating T Cell Responses by Targeting CD3. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/36831533 | PubMed |
| 20068406 | Preclinical evaluation of light-activatable, bispecific anti-human CD3 antibody conjugates as anti-ovarian cancer therapeutics. | MAbs | 2009 | https://conductscience.org/library/papers/20068406 | PubMed |
| 18778286 | Retinoic acid inhibits in vivo interleukin-2 gene expression and T-cell activation in mice. | Immunology | 2009 | https://conductscience.org/library/papers/18778286 | PubMed |
| 11961670 | Tumor gene therapy by MVA-mediated expression of T-cell-stimulating antibodies. | Cancer Gene Ther | 2002 | https://conductscience.org/library/papers/11961670 | PubMed |
| 11371607 | CD3-mediated activation of tumor-reactive lymphocytes from patients with advanced cancer. | Proc Natl Acad Sci U S A | 2001 | https://conductscience.org/library/papers/11371607 | PubMed |
| 9159146 | A lymphocyte-activating monoclonal antibody induces regression of human tumors in severe combined immunodeficient mice. | Proc Natl Acad Sci U S A | 1997 | https://conductscience.org/library/papers/9159146 | PubMed |
| 8608651 | In vitro T cell unresponsiveness following low-dose injection of anti-CD3 MoAb. | Clin Exp Immunol | 1996 | https://conductscience.org/library/papers/8608651 | PubMed |
| 8535054 | The role of the immune system in anti-tumour responses. Potential for drug therapy. | Drugs Aging | 1995 | https://conductscience.org/library/papers/8535054 | PubMed |
| 8514611 | Effect of accessory cells on stimulation of murine T-cell leukemia with antibodies to the CD3/T cell antigen receptor complex. | Jpn J Cancer Res | 1993 | https://conductscience.org/library/papers/8514611 | PubMed |
| 8514380 | An anti-CD3 monoclonal antibody protects mice against a lethal infection with Listeria monocytogenes through induction of endogenous cytokines. | Infect Immun | 1993 | https://conductscience.org/library/papers/8514380 | PubMed |
| 8425213 | Superantigen-based tumor therapy: in vivo activation of cytotoxic T cells. | Cancer Immunol Immunother | 1993 | https://conductscience.org/library/papers/8425213 | PubMed |
| 8299119 | Poor induction of interleukin-2 receptor expression on CD8bright+ cells in whole blood cell cultures with CD3 mAb. Implications for immunotherapy with CD3 mAb. | Cancer Immunol Immunother | 1994 | https://conductscience.org/library/papers/8299119 | PubMed |
| 8124689 | Colon adenocarcinoma cells inhibit anti-CD3-activated killer cell induction. | Cancer Immunol Immunother | 1994 | https://conductscience.org/library/papers/8124689 | PubMed |
| 8058730 | Immunotherapy with anti-CD3 monoclonal antibodies and recombinant interleukin 2: stimulation of molecular programs of cytotoxic killer cells and induction of tumor regression. | Proc Natl Acad Sci U S A | 1994 | https://conductscience.org/library/papers/8058730 | PubMed |
| 7954522 | The immunobiological effects of interleukin-2 in vivo. | Cancer Immunol Immunother | 1994 | https://conductscience.org/library/papers/7954522 | PubMed |
| 7684652 | Eradication of metastatic tumour cells from lymph nodes by local administration of anti-CD3 antibody. | Cancer Immunol Immunother | 1993 | https://conductscience.org/library/papers/7684652 | PubMed |
| 1899481 | In vivo T-cell activation by staphylococcal enterotoxin B prevents outgrowth of a malignant tumor. | Proc Natl Acad Sci U S A | 1991 | https://conductscience.org/library/papers/1899481 | PubMed |
| 1830862 | Alpha beta T-lymphocyte depleted mice, a model for gamma delta T-lymphocyte functional studies. | Immunol Rev | 1991 | https://conductscience.org/library/papers/1830862 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/2902689
GET https://conductscience.org/api/papers/v1/2902689/authors